{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Dapagliflozin",
        "type": {
          "id": "d64f59e2-3704-4773-b51a-2b8910acbb07",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "3b4fb2e1-53d2-4ce2-b7bb-ee05de55d8a9",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Highly selective and reversible inhibitor of human renal SGLT2 for the treatment of chronic heart failure with reduced ejection fraction (HFrEF).",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "c50e2f2c-f42c-4ad9-97ba-3037d90bc305",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "09e2fd2b-331d-437e-8838-e24b37d085a1",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo tablets identical in size, color, smell, and taste to dapagliflozin.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Standard of Care Therapy",
        "type": {
          "id": "60a7d1f1-f733-4e26-bb8e-5a5f193fae3f",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "3ac967e4-288c-4866-b707-eb21852ea372",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Regional standard of care for heart failure, including ACE inhibitors, ARBs, sacubitril/valsartan, beta-blockers, and MRAs."
      },
      {
        "id": "int_4",
        "name": "Diuretics",
        "type": {
          "id": "72244360-30b5-42d5-b04d-3c93168bc503",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "d6175ae6-958e-4a34-9f55-642bad6b3dda",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted and expected for volume control; doses may be titrated as clinically indicated."
      },
      {
        "id": "int_5",
        "name": "SGLT2 inhibitors (open-label)",
        "type": {
          "id": "8e0a8ebd-8dd7-48e8-95c3-f94276eb721c",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "1d6d3a6d-6b4e-4988-b4b6-65a82946ccfb",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited in combination with IP; should be avoided during the course of the study."
      },
      {
        "id": "int_6",
        "name": "NSAIDs",
        "type": {
          "id": "fac723c4-0c80-4146-b239-8fd614ebf2b9",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "172e9731-c8e7-4e2b-8d11-b27f0dd4dd11",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Use should be re-considered if unexpected acute decline in kidney function occurs."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Dapagliflozin tablets",
        "administrableDoseForm": {
          "id": "77b687d7-4694-498a-99b4-d7f0d817beaf",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "4d00a5d7-4359-4d0c-acb9-d6f0db9caea3",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "ed4ab33a-a869-4b6b-a08d-19965d5b4bdf",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "10 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "AstraZeneca"
      },
      {
        "id": "prod_2",
        "name": "Dapagliflozin tablets",
        "administrableDoseForm": {
          "id": "495dd377-fa35-4555-b53d-9b5caa827b2c",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "ec573873-a080-4c23-abcf-2c4f1c566a10",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "dd860068-ecaf-4e45-9bf1-1a168fd854a5",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "5 mg",
        "manufacturer": "AstraZeneca"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Dapagliflozin 10 mg daily",
        "instanceType": "Administration",
        "dose": "10 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Estimated mean treatment period of 24 months (event-driven study)"
      },
      {
        "id": "admin_2",
        "name": "Dapagliflozin 5 mg daily",
        "instanceType": "Administration",
        "dose": "5 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Temporary use when clinically indicated (e.g., volume depletion or renal concerns)"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Dapagliflozin",
        "instanceType": "Substance",
        "description": "Sodium glucose co-transporter 2 (SGLT2) inhibitor"
      }
    ],
    "medicalDevices": [
      {
        "id": "dev_1",
        "name": "Cardiac Resynchronization Therapy (CRT)",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      },
      {
        "id": "dev_2",
        "name": "Ventricular Assistance Device (VAD)",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      }
    ],
    "summary": {
      "interventionCount": 6,
      "productCount": 2,
      "deviceCount": 2
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Dapagliflozin",
        "role": "Investigational Product",
        "description": "Highly selective and reversible inhibitor of human renal SGLT2 for the treatment of chronic heart failure with reduced ejection fraction (HFrEF)."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo tablets identical in size, color, smell, and taste to dapagliflozin."
      },
      {
        "name": "Standard of Care Therapy",
        "role": "Background Therapy",
        "description": "Regional standard of care for heart failure, including ACE inhibitors, ARBs, sacubitril/valsartan, beta-blockers, and MRAs."
      },
      {
        "name": "Diuretics",
        "role": "Concomitant Medication",
        "description": "Permitted and expected for volume control; doses may be titrated as clinically indicated."
      },
      {
        "name": "SGLT2 inhibitors (open-label)",
        "role": "Concomitant Medication",
        "description": "Prohibited in combination with IP; should be avoided during the course of the study."
      },
      {
        "name": "NSAIDs",
        "role": "Concomitant Medication",
        "description": "Use should be re-considered if unexpected acute decline in kidney function occurs."
      }
    ],
    "products": [
      {
        "name": "Dapagliflozin tablets",
        "doseForm": "Tablet",
        "strength": "10 mg",
        "manufacturer": "AstraZeneca"
      },
      {
        "name": "Dapagliflozin tablets",
        "doseForm": "Tablet",
        "strength": "5 mg",
        "manufacturer": "AstraZeneca"
      }
    ],
    "substances": [
      {
        "name": "Dapagliflozin",
        "description": "Sodium glucose co-transporter 2 (SGLT2) inhibitor"
      }
    ],
    "administrations": [
      {
        "name": "Dapagliflozin 10 mg daily",
        "dose": "10 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Estimated mean treatment period of 24 months (event-driven study)"
      },
      {
        "name": "Dapagliflozin 5 mg daily",
        "dose": "5 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Temporary use when clinically indicated (e.g., volume depletion or renal concerns)"
      }
    ],
    "devices": [
      {
        "name": "Cardiac Resynchronization Therapy (CRT)",
        "manufacturer": "Not specified",
        "purpose": "Device therapy for heart failure management"
      },
      {
        "name": "Ventricular Assistance Device (VAD)",
        "manufacturer": "Not specified",
        "purpose": "Mechanical circulatory support (exclusion criteria if implanted prior to randomization)"
      }
    ]
  }
}